Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987164 | 0.86 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1AHCYP2RX3 | |
| SCHEMBL19987333 | 0.84 | NT5E (0.45) | CYP3A4CYP2C9 | |
| SCHEMBL19987319 | 0.84 | CYP3A4 (0.42) | CYP3A4CYP2C9BTN3A1P2RX3P2RX2 | |
| SCHEMBL21136329 | 0.81 | CYP3A4 (0.48) | CYP3A4CYP2C9BTN3A1AHCYP2RY12 | |
| SCHEMBL21136331 | 0.81 | CYP3A4 (0.48) | CYP3A4CYP2C9BTN3A1AHCYP2RY12 | |
| SCHEMBL19987217 | 0.81 | CYP3A4 (0.48) | CYP3A4CYP2C9BTN3A1AHCYP2RY12 | |
| SCHEMBL19987310 | 0.81 | CYP3A4 (0.48) | CYP3A4CYP2C9BTN3A1AHCYP2RX3 | |
| SCHEMBL19987288 | 0.81 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1AHCYP2RX3 | |
| SCHEMBL22224910 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1AHCYP2RY12 | |
| SCHEMBL21136231 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1AHCYP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |